RFL case: Fortis promoter Malvinder Singh's representation on bail criteria rejected

He was arrested for alleged misappropriation of funds from the Religare Finvest Ltd (RFL).FIRs have also been registered against him for the offences of cheating and money laundering.

Published On 2020-06-22 11:20 GMT   |   Update On 2020-06-22 11:20 GMT

New Delhi - A High Powered Committee (HPC), headed by a Delhi High Court judge, has rejected the representation of former Fortis promoter Malvinder Mohan Singh challenging its criteria for grant of interim bail to under-trial prisoners (UTPs).

Singh moved the representation after his plea for interim bail was denied by the high court which gave him liberty to approach the committee if he was aggrieved by the criteria laid down by it.

Read Also: Delhi court denies bail to ex-Fortis Healthcare Promoter Shivinder Singh in RFL case

He was arrested for alleged misappropriation of funds from the Religare Finvest Ltd (RFL).FIRs have also been registered against him for the offences of cheating and money laundering.

The HPC said that when the Supreme Court ordered setting up of such committees, to look into decongesting prisons to prevent spread of COVID-19, it gave the panels "an absolute discretion" to determine which class/category of prisoners can be released on interim bail or parole.

Advertisement

"In view thereof, this Committee is of the opinion that the representation is unmerited and the same is accordingly rejected," it added.

The HPC said that Singh was at liberty to file a bail application before courts concerned, which shall consider the same on merits in accordance with the law. 

Read Also: COVID-19 outbreak: Fortis Healthcare reports fall in hospital occupancy


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News